IP Library Patent Application 16813813
Patent Application
App. No. 16/813,813

ORAL LIQUID FORMULATIONS OF TACROLIMUS AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/813,813
Filed
Mar 10, 2020
Art Unit
1626
USPC
514/291
Abstract

The present disclosure relates to oral liquid tacrolimus formulations and the use in treating organ or stem cell transplant recipients or T-cell mediated diseases.

Claims (14)

1 . An oral liquid dosage formulation comprising:

(a) tacrolimus;

(b) one or more pharmaceutically acceptable solubilizers; and

(c) optionally one or more pharmaceutically acceptable excipients selected from the group consisting of flavoring agents, sweeteners, preservatives, buffering agents, pH adjusting agents, dispersants, carriers or combinations thereof wherein the formulation is a non-aqueous solution.

2 . The oral liquid dosage formulation of claim 1 wherein the one or more pharmaceutically acceptable solubilizers are selected from the group consisting of selected from the group consisting of polyethylene glycols, propylene glycol, glycerin, triacetin, ethanol, polysorbates, oils and combinations thereof.

3 . The oral liquid dosage formulation of claim 2 wherein the one or more pharmaceutically acceptable solubilizers are selected from the group consisting of selected from the group consisting of polyethylene glycols, propylene glycol, glycerin, triacetin, oils and combinations thereof.

4 . The oral liquid dosage formulation of claim 1 wherein the one or more pharmaceutically acceptable solubilizers are liquid at room temperature.

5 . The oral liquid dosage formulation of claim 1 wherein the formulation is substantially free of a surfactant, wetting agent or emulsifying agent.

6 . The oral liquid dosage formulation of claim 1 wherein the formulation is substantially free of low molecular weight mono alcohols.

7 . An oral liquid dosage formulation comprising:

(a) tacrolimus;

(b) one or more pharmaceutically acceptable solubilizers selected from the group consisting of selected from the group consisting of polyethylene glycols, propylene glycol, glycerin, triacetin, ethanol, polysorbates, oils and combinations thereof; and

(c) optionally one or more pharmaceutically acceptable excipients selected from the group consisting of flavoring agents, sweeteners, preservatives, buffering agents, pH adjusting agents, or combinations thereof

wherein the formulation is a non-aqueous solution, free of a surfactant, wetting agent, emulsifying agent and low molecular weight mono alcohols.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jun 10, 2022
From: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; GEMINI LABORATORIES LLC
To: TRUIST BANK. AS ADMINISTRATIVE AGENT
Reel/Frame 060329/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2020
From: PATEL, HARDIK; PATEL, AMITKUMAR; PATEL, SUHASKUMAR
To: GEMINI LABORATORIES, LLC
Reel/Frame 053992/0741 →